The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) voted this week in favor of renewing the recommendation for FluMist Quadrivalent in the United States for the 2018-2019 influenza season, according to an announcement by the pharmaceutical company AstraZeneca.
FluMist is the only needle-free flu vaccine on the U.S. market. It had been removed from circulation the past two years amid concerns about its effectiveness. According to a recent study, the vaccine performed significantly better against one strain of this year’s flu pandemic (A/Slovenia) than it had against the A/Bolivia strain in 2015-2016.
FluMist is a nasal spray vaccine approved by the U.S. Food and Drug Administration for use in children and adults between ages 2 and 49. The recommendations will now be sent to the director of the CDC and the U.S. Department of Health and Human Services for review and approval.